US20130331599A1 - Compound for preparing 4-(10b)borono-l-phenylalanine - Google Patents

Compound for preparing 4-(10b)borono-l-phenylalanine Download PDF

Info

Publication number
US20130331599A1
US20130331599A1 US13/910,284 US201313910284A US2013331599A1 US 20130331599 A1 US20130331599 A1 US 20130331599A1 US 201313910284 A US201313910284 A US 201313910284A US 2013331599 A1 US2013331599 A1 US 2013331599A1
Authority
US
United States
Prior art keywords
group
compound
borono
phenylalanine
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/910,284
Inventor
Chia-Cheng Shaw
Kuen-Wang Sheu
Shu-Fen Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Biotech Co Ltd
Original Assignee
Taiwan Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Biotech Co Ltd filed Critical Taiwan Biotech Co Ltd
Priority to US13/910,284 priority Critical patent/US20130331599A1/en
Assigned to TAIWAN BIOTECH CO., LTD. reassignment TAIWAN BIOTECH CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUANG, SHU-FEN, SHAW, CHIA-CHENG, Sheu, Kuen-Wang
Publication of US20130331599A1 publication Critical patent/US20130331599A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a compound for preparing 4-( 10 B)borono-L-phenylalanine ( L - 10 BPA), particularly to a compound for preparing L - 10 BPA with high isotopic purity and high optical purity.
  • L -BPA 4-Borono-L-phenylalanine
  • BNCT boron neutron capture therapy
  • 10 B contained in L -BPA is known as the critical factor accumulated in tumor cells and subsequently irradiated with thermal neutron.
  • BNCT boron neutron capture therapy
  • natural boron exists as 19.9% of 10 B isotope and 80.1% of 11 B isotope. Therefore, many researchers have been developing synthetic processes and compounds suitable for producing 10 B-enriched L -BPA.
  • the boron source for producing the intermediate is bis(pinacolato)diboron and 4,4′,6,6′-tetraphenyl-2,2′-bi(1,3,2,-dioxaborinane), which is not commercial available and is hardly prepared from reacting diboron with propane diols. Therefore, such disclosed preparation is difficult and time-consuming.
  • the present invention provides a compound for preparing 4-( 10 B)borono-L-phenylalanine to mitigate or obviate the aforementioned problems.
  • one objective of the present invention is to provide a compound for preparing 4-( 10 B)borono-L-phenylalanine in a facile method and without tedious hydrogenation. Accordingly, the compound of the present invention is applicable for preparing 4-( 10 B)borono-L-phenylalanine and the obtained 4-( 10 B)borono-L-phenylalanine has high isotopic purity and high optical purity.
  • the compound for preparing 4-( 10 B)borono-L-phenylalanine in accordance with the present invention is of formula (I):
  • R group represents a protecting group and is selected from the group consisting of: tert-butoxycarbonyl (Boc) group, trityl (Trt) group, 3,5-dimethoxyphenylisopropoxycarbonyl(Ddz) group, 2-(4-Biphenyl)isopropoxycarbonyl (Bpoc) group, and 2-nitrophenylsulfenyl (Nps) group, and the compound has a 10 B purity higher than or equal to 98%.
  • the present invention provides a novel compound for preparing 4-( 10 B)borono-L-phenylalanine, particularly to a compound that is easy to be prepared such as from commercially available starting materials, and the compound of the present invention is with high isotopic purity and high optical purity. Furthermore, the compound in accordance with the present invention provides 4-( 10 B)borono-L-phenylalanine by undergoing simple deprotection step such as an acid deprotection step, and the obtained 4-( 10 B)borono-L-phenylalanine is with high isotopic purity and high optical purity. Accordingly, the compound is applicable for preparing 4-( 10 B)borono-L-phenylalanine.
  • the compound has an enantiomeric excess higher than or equal to 99%.
  • the R group is tert-butoxycarbonyl (t-Boc) group.
  • the present invention provides solutions to solve the problems of the conventional processes for preparing 4-( 10 B)borono-L-phenylalanine.
  • a compound for preparing 4-( 10 B)borono-L-phenylalanine from (S)-N-Boc-4-iodophenylalanine is provided as a preferred embodiment for illustrating but not limiting the scope of the present invention.
  • the resulted mixture was filtered to remove insoluble solid, and 100 mL of water was adopted for transfer and rinse.
  • the obtained filtrate was transferred to a separatory funnel to separate the layers, and the basic lower aqueous layer was separated to obtain a first aqueous layer.
  • the first aqueous layer was extracted with isobutyl alcohol and then separated from the isobutyl alcohol to obtain a second aqueous layer.
  • the pH of the second aqueous layer was adjusted to 3 to 4 by using 37% hydrochloric acid at a temperature ranging from 20° C. to 25° C., the product (S)-N-Boc-4-( 10 B) boronophenylalanine started to precipitate during this period.
  • the second aqueous layer mixture was stirred for 30 minutes, then the pH of the second aqueous layer mixture was further adjusted to 3.0 and then the second aqueous layer mixture was stirred for another 2 hours.
  • the second aqueous layer mixture was filtered to obtain solid (S)-N-Boc-4-( 10 B) boronophenylalanine, which was then washed twice with water and dried in a vacuum oven at 50° C.
  • the temperature of the acidic mixture was cooled to room temperature, and the pH of the acidic mixture was adjusted to 1.5 by using sodium hydroxide aqueous solution, 4-( 10 B)borono-L-phenylalanine started to precipitate during this period, and the acidic mixture was stirred for 50 min.
  • the pH of the acidic mixture was readjusted to 6.2 by using sodium hydroxide aqueous solution, and the mixture was stirred for a minimum of 25 minutes at room temperature.
  • the acidic mixture was filtered to obtain solid 4-( 10 B)borono-L-phenylalanine.
  • the melting point, specific rotation, 1 H NMR data, 13 C NMR data, IR data, ICP-MS data and HRMS data of the obtained L-(10B) BPA are as follows.
  • IR(KBr) ⁇ max 3585, 3148, 3038, 2923, 1636, 1610, 1507, 1410, 1398, 1345, 1085, 716 cm ⁇ 1 .
  • ICP-MS measurements for 10 B content is higher than 99.4 (w/w %), wherein 10 B is compared to 11 B;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Provided is a compound of the following formula (I) for preparing 4-(10B)borono-L-phenylalnine:
Figure US20130331599A1-20131212-C00001
wherein R group represents a protecting group and is selected from the group consisting of: tert-butoxycarbonyl (Boc) group, trityl (Trt) group, 3,5-dimethoxyphenylisopropoxycarbonyl(Ddz) group, 2-(4-Biphenyl)isopropoxycarbonyl (Bpoc) group, and 2-nitrophenylsulfenyl (Nps) group, and the compound has a 10B purity higher than or equal to 98% and an enantiomeric excess higher than or equal to 99%.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • Pursuant to 35 U.S.C. §119(e), this application claims the benefit of U.S. Provisional Patent Application No. 61/657,069, filed Jun. 08, 2012. The content of the prior application is incorporated herein by its entirety.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to a compound for preparing 4-(10B)borono-L-phenylalanine (L-10BPA), particularly to a compound for preparing L-10BPA with high isotopic purity and high optical purity.
  • 2. Description of the Prior Arts
  • 4-Borono-L-phenylalanine (L-BPA) is an important boronated compound known to be useful for treatment of cancer through boron neutron capture therapy (BNCT). Furthermore, 10B contained in L-BPA is known as the critical factor accumulated in tumor cells and subsequently irradiated with thermal neutron. Thus 10B renders L-BPA a treatment of cancer through boron neutron capture therapy (BNCT). However, natural boron exists as 19.9% of 10B isotope and 80.1% of 11B isotope. Therefore, many researchers have been developing synthetic processes and compounds suitable for producing 10B-enriched L-BPA.
  • Nevertheless, most conventional synthetic processes and compounds are not applicable for producing 4-(10B)borono-L-phenylalanine (L-10BPA) but only applicable for producing 4-borono-L-phenylalanine (L-BPA). For example, U.S. Pat. No.6,031,127 discloses a process and an intermediate for preparing 4-borono-L-phenylalanine (L-BPA), wherein the intermediate is of formula (A):
  • Figure US20130331599A1-20131212-C00002
  • According to the disclosure, the boron source for producing the intermediate is bis(pinacolato)diboron and 4,4′,6,6′-tetraphenyl-2,2′-bi(1,3,2,-dioxaborinane), which is not commercial available and is hardly prepared from reacting diboron with propane diols. Therefore, such disclosed preparation is difficult and time-consuming.
  • To overcome the shortcomings, the present invention provides a compound for preparing 4-(10B)borono-L-phenylalanine to mitigate or obviate the aforementioned problems.
  • SUMMARY OF THE INVENTION
  • Given that the aforesaid drawbacks of the prior art such as difficulties of preparing L-10BPA, needs for hydrogenation to provide 4-borono-L-phenylalanine, and thus being inapplicable for producing 10B-enriched L-BPA, one objective of the present invention is to provide a compound for preparing 4-(10B)borono-L-phenylalanine in a facile method and without tedious hydrogenation. Accordingly, the compound of the present invention is applicable for preparing 4-(10B)borono-L-phenylalanine and the obtained 4-(10B)borono-L-phenylalanine has high isotopic purity and high optical purity.
  • To achieve the aforementioned objective, the compound for preparing 4-(10B)borono-L-phenylalanine in accordance with the present invention is of formula (I):
  • Figure US20130331599A1-20131212-C00003
  • wherein R group represents a protecting group and is selected from the group consisting of: tert-butoxycarbonyl (Boc) group, trityl (Trt) group, 3,5-dimethoxyphenylisopropoxycarbonyl(Ddz) group, 2-(4-Biphenyl)isopropoxycarbonyl (Bpoc) group, and 2-nitrophenylsulfenyl (Nps) group, and the compound has a 10B purity higher than or equal to 98%.
  • The present invention provides a novel compound for preparing 4-(10B)borono-L-phenylalanine, particularly to a compound that is easy to be prepared such as from commercially available starting materials, and the compound of the present invention is with high isotopic purity and high optical purity. Furthermore, the compound in accordance with the present invention provides 4-(10B)borono-L-phenylalanine by undergoing simple deprotection step such as an acid deprotection step, and the obtained 4-(10B)borono-L-phenylalanine is with high isotopic purity and high optical purity. Accordingly, the compound is applicable for preparing 4-(10B)borono-L-phenylalanine.
  • Preferably, the compound has an enantiomeric excess higher than or equal to 99%.
  • Preferably, the R group is tert-butoxycarbonyl (t-Boc) group.
  • Other objectives, advantages and novel features of the invention will become more apparent from the following detailed description when taken in conjunction with the accompanying drawings.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention provides solutions to solve the problems of the conventional processes for preparing 4-(10B)borono-L-phenylalanine. A compound for preparing 4-(10B)borono-L-phenylalanine from (S)-N-Boc-4-iodophenylalanine is provided as a preferred embodiment for illustrating but not limiting the scope of the present invention.
  • For a better understanding about the technical features of the present invention and its effect, and for implements in accordance with the disclosures of the specification, preferred embodiment, details and figures are further shown as follows.
  • Embodiment 1 Preparation of (S)-N-Boc-4-(10B) boronophenylalanine of formula (a) from (S)-N-Boc-4-iodophenylalanine of formula (b)
  • Figure US20130331599A1-20131212-C00004
  • Set up a 3-L, three-necked flask equipped with a mechanical stirrer, a thermometer, and a nitrogen inlet adaptor capped with a rubber septum. Charge the flask with 2-methyltetrahydrofuran (750 mL), followed by (S)-N-Boc-4-iodophenylalanine (50.0 g, 100% pure, 128 mmol), stirred to form a solution, and added tributyl 10B borate (99% of 10B purity, 106 mL, 90.1 g, 393 mmol) to form a mixed solution. The mixed solution was cooled to a temperature ranging from −76° C. to −85° C., and n-butyllithium (1.6 M in hexanes, 375 ml, 600 mmol) was added dropwise to the mixed solution over 3 h to form a reaction mixture. After the addition, the reaction mixture was stirred for an additional 0.5 h at −80° C. HPLC analysis of a quenched sample of the reaction mixture showed the starting material (S)-N-Boc-4-iodophenylalanine was less than 0.5%. The reaction mixture was quenched slowly with 900 mL of cold water over 15 to 20 min, then allowed to warm to a temperature ranging from 5° C. to 10° C. The resulted mixture was filtered to remove insoluble solid, and 100 mL of water was adopted for transfer and rinse. The obtained filtrate was transferred to a separatory funnel to separate the layers, and the basic lower aqueous layer was separated to obtain a first aqueous layer. The first aqueous layer was extracted with isobutyl alcohol and then separated from the isobutyl alcohol to obtain a second aqueous layer.
  • The pH of the second aqueous layer was adjusted to 3 to 4 by using 37% hydrochloric acid at a temperature ranging from 20° C. to 25° C., the product (S)-N-Boc-4-(10B) boronophenylalanine started to precipitate during this period. The second aqueous layer mixture was stirred for 30 minutes, then the pH of the second aqueous layer mixture was further adjusted to 3.0 and then the second aqueous layer mixture was stirred for another 2 hours. The second aqueous layer mixture was filtered to obtain solid (S)-N-Boc-4-(10B) boronophenylalanine, which was then washed twice with water and dried in a vacuum oven at 50° C. for a minimum of 4 hours to an LOD of less than 0.5% to afford 25.8 g of (S)-N-Boc-4-(10B) boronophenylalanine as white solid, which was 99.6% pure determined by HPLC. The yield was 65.1%.
  • The melting point, specific rotation, 1H NMR data, 13C NMR data, IR data and MS data of the obtained (S)-N-Boc-4-(10B) boronophenylalanine are as follows.
  • Melting point: 150° C. (decomp.);
  • [α]25 D:+14° (c=0.5, MeOH);
  • 1H NMR:(500 MHz, DMSO-d6):δ 8.0 (s, 2H), 7.7 (d, J=7.7 Hz, 2H), 7.2 (d, J=7.6 Hz, 2H), 7.0 (d, J=8.4 Hz, 2H), 4.1 (m, 1H), 3.0 (dd, J=13.8, 4.5 Hz, 1H), 2.8 (dd, J=13.7, 10.3 Hz, 1H), 1.3 (s, 9H);
  • 13C NMR (125 MHz, DMSO-d6) δ 173.63, 155.48, 139.96, 134.06, 131.94, 128.18, 78.13, 55.06, 36.53, 28.19;
  • IR (KBr) νmax: 3331, 2979, 1717, 1689, 1537, 1399, 1372, 1365, 1285, 1165, 1045 cm−1; and
  • HRMS (ESI): calculated for C14H20 10BNO6 [M-H]307.1420, found 307.1333.
  • Preparation of 4-(10B)borono-L-phenylalanine (L-(10B) BPA) from (S)-N-Boc-4-(10B)boronophenylalanine
  • A suspension of (S)-N-Boc-4-(10B) boronophenylalanine (20.5 g, 99.6% pure, 66.2 mmol) in a mixture of acetone (122 ml) and water (14 ml) was stirred at room temperature and added hydrochloric acid (37%, 13.9 14 ml) to form an acidic mixture, the acidic mixture was stirred at 55° C. for 1.5 to 2 hours. HPLC analysis of the acidic mixture showed the completion of the reaction. The temperature of the acidic mixture was cooled to room temperature, and the pH of the acidic mixture was adjusted to 1.5 by using sodium hydroxide aqueous solution, 4-(10B)borono-L-phenylalanine started to precipitate during this period, and the acidic mixture was stirred for 50 min. The pH of the acidic mixture was readjusted to 6.2 by using sodium hydroxide aqueous solution, and the mixture was stirred for a minimum of 25 minutes at room temperature. The acidic mixture was filtered to obtain solid 4-(10B)borono-L-phenylalanine. The solid 4-(10B)borono-L-phenylalanine was washed with 50% aqueous acetone, followed by an acetone rinse, dried in a vacuum oven at 80° C. for a minimum of 6 hours to constant weight to afford 13.3 g (95.2% yield) of 4-(10B)borono-L-phenylalanine with 99.9% pure as white crystals, and was analyzed by chiral HPLC, indicating the ratio of L to D isomers to be 100 to 0 (100% enantiometric excess).
  • The melting point, specific rotation, 1H NMR data, 13C NMR data, IR data, ICP-MS data and HRMS data of the obtained L-(10B) BPA are as follows.
  • Melting point: 275 to 280° C. (decomp.);
  • [α]25 D:−5.4° (c=0.5, 1M HCl);
  • 1H NMR (500 MHz, D2O, CF3COOD):δ 7.2 (d, J=8.0 Hz, 2H), 6.8 (d, J=8.0 Hz, 2H), 3.9 (dd, J=7.8, 5.7 Hz, 1H), 2.8 (dd, J=14.6, 5.6 Hz, 1H), 2.7 (dd, J=14.6, 7.9 Hz, 1H);
  • 13C NMR: (125 MHz, D2O, CF3COOD):δ171.80, 137.31, 135.16, 132.37, 129.65, 54.64, 36.32;
  • IR(KBr) νmax: 3585, 3148, 3038, 2923, 1636, 1610, 1507, 1410, 1398, 1345, 1085, 716 cm−1.
  • ICP-MS measurements for 10B content is higher than 99.4 (w/w %), wherein 10B is compared to 11B; and
  • HRMS (ESI): calculated for C9H1310BNO4, [M+H]+ 209.0974, found 209.0970.
  • Even though numerous characteristics and advantages of the present invention have been set forth in the foregoing description, together with details of the structure and features of the invention, the disclosure is illustrative only. Changes may be made in the details, especially in matters of shape, size, and arrangement of parts within the principles of the invention to the full extent indicated by the broad general meaning of the terms in which the appended claims are expressed.

Claims (4)

What is claimed is:
1. A compound of the following formula (I) for preparing 4-(10B)borono-L-phenylalnine :
Figure US20130331599A1-20131212-C00005
wherein R group is selected from the group consisting of:
tert-butoxycarbonyl (t-Boc) group, trityl (Trt) group,
3,5-dimethoxyphenylisopropoxycarbonyl(Ddz) group,
2-(4-Biphenyl)isopropoxycarbonyl (Bpoc) group, and 2-nitrophenylsulfenyl (Nps) group, and the compound has a 10B purity higher than or equal to 98%.
2. The compound according to claim 1, wherein the compound has an enantiomeric excess higher than or equal to 99%.
3. The compound according to claim 1, wherein the R group is tert-butoxycarbonyl (t-Boc) group.
4. The compound according to claim 2, wherein the R group is tert-butoxycarbonyl (t-Boc) group.
US13/910,284 2012-06-08 2013-06-05 Compound for preparing 4-(10b)borono-l-phenylalanine Abandoned US20130331599A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/910,284 US20130331599A1 (en) 2012-06-08 2013-06-05 Compound for preparing 4-(10b)borono-l-phenylalanine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657069P 2012-06-08 2012-06-08
US13/910,284 US20130331599A1 (en) 2012-06-08 2013-06-05 Compound for preparing 4-(10b)borono-l-phenylalanine

Publications (1)

Publication Number Publication Date
US20130331599A1 true US20130331599A1 (en) 2013-12-12

Family

ID=49715832

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/910,233 Active US8765997B2 (en) 2012-06-08 2013-06-05 Process for preparing 4-borono-L-phenylalanine
US13/910,284 Abandoned US20130331599A1 (en) 2012-06-08 2013-06-05 Compound for preparing 4-(10b)borono-l-phenylalanine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/910,233 Active US8765997B2 (en) 2012-06-08 2013-06-05 Process for preparing 4-borono-L-phenylalanine

Country Status (1)

Country Link
US (2) US8765997B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323046B2 (en) 2015-08-14 2019-06-18 Neuboron Medtech Ltd. Method for preparing L-BPA

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220003507A (en) 2019-03-04 2022-01-10 티에이이 라이프 사이언시스 Borylated Amino Acid Compositions and Methods Thereof for Use in Boron Neutron Capture Therapy
JP7297077B2 (en) * 2019-04-26 2023-06-23 南京中硼▲聯▼康医▲療▼科技有限公司 BPA freeze-dried formulation and manufacturing method
WO2023009172A1 (en) 2021-07-30 2023-02-02 TAE Life Sciences Borylated amino acid compositions comprising bts and bts(ome) for use in boron neutron capture therapy and methods thereof
CN118843479A (en) 2021-12-16 2024-10-25 Tae生命科学有限责任公司 Boronated dipeptide amino acid compositions and methods for boron neutron capture therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Shapiro et al. (Mass Spectrometry in Boron Chemistry, 1961) *
STN (24 March 1989, STN registry reference obtained 6/9/2014) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323046B2 (en) 2015-08-14 2019-06-18 Neuboron Medtech Ltd. Method for preparing L-BPA

Also Published As

Publication number Publication date
US20130331602A1 (en) 2013-12-12
US8765997B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
CN106467556B (en) The preparation method of L-BPA
US20130331599A1 (en) Compound for preparing 4-(10b)borono-l-phenylalanine
CN106188116A (en) A kind of method of synthesizing pyrazole 4 boric acid pinacol ester
US20160023984A1 (en) Manufacturing method of ester compound
EP2865682B1 (en) Process for preparing 4-Borono-L-Phenylalanine
US20120289733A1 (en) Novel borate derivatives and their applications
US9108990B2 (en) Cyclopropyl MIDA boronate
CN104447823A (en) 4 - dihydroxy boryl - L-phenylalanine preparation method
EP2865683B1 (en) Compounds for preparing 4-(10b)borono-l-phenylalanine
TWI480283B (en) Process for preparing 4-borono-l-phenylalanine
CN110498810B (en) Preparation method of L-BPA
TWI464175B (en) Compound for preparing 4-(b)borono-l-phenylalanine
US20190119244A1 (en) Process for preparing intermediates useful in the synthesis of antifungal drugs
CN104447822A (en) Compound for preparation of 4 - (10 B) dihydroxy boryl- L - phenylalanine
US11453687B2 (en) Production method of biarylphosphine
CN113185518B (en) Synthesis method of dipyridamole Mo Zazhi I, II
US20240336635A1 (en) Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]-cyclohexane-1-carboxylic acid
TWI834476B (en) Intermediate, preparing method thereof, and method of preparing drug
WO2022102565A1 (en) Method for producing 4-borono-l-phenylalanine and intermediate thereof
US20230234973A1 (en) Intermediate, preparing method thereof, and method of preparing drug
JP2022554245A (en) Amorphous solid succinylated 3-(fatty acid amide)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making them
CN115010621A (en) Synthetic method of 4-bromo-3-methylbenzonitrile
CN112778177A (en) High-quality fudosteine impurity standard substance and preparation method thereof
CN108840832A (en) A kind of preparation method of Gadobutrol intermediate
CN102276650A (en) Preparation method of zoledronic acid

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAIWAN BIOTECH CO., LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHAW, CHIA-CHENG;SHEU, KUEN-WANG;HUANG, SHU-FEN;REEL/FRAME:030548/0644

Effective date: 20130502

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION